3-hydroxypregn-4-en-20-one has been researched along with fluoxetine in 1 studies
Studies (3-hydroxypregn-4-en-20-one) | Trials (3-hydroxypregn-4-en-20-one) | Recent Studies (post-2010) (3-hydroxypregn-4-en-20-one) | Studies (fluoxetine) | Trials (fluoxetine) | Recent Studies (post-2010) (fluoxetine) |
---|---|---|---|---|---|
29 | 0 | 2 | 10,100 | 1,663 | 3,263 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Griffin, LD; Mellon, SH | 1 |
1 other study(ies) available for 3-hydroxypregn-4-en-20-one and fluoxetine
Article | Year |
---|---|
Biosynthesis of the neurosteroid 3 alpha-hydroxy-4-pregnen-20-one (3 alpha hp), a specific inhibitor of FSH release.
Topics: 20-alpha-Dihydroprogesterone; 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific); 3-Hydroxysteroid Dehydrogenases; Animals; Cholestenone 5 alpha-Reductase; Enzymes; Female; Fluoxetine; Follicle Stimulating Hormone; Humans; Oxidoreductases; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors; Tissue Distribution | 2001 |